Pacmilimab

帕克米利单抗

Report date: 2026/04/29 20:02:18

Base Information

Drug NamePacmilimab

Drug Alias NameCX-072

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody polypeptide conjugate (APC)

Mechanisms of ActionProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUkrainePoland +[8]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCytomx Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCytomx Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms

Inactive IndicationsSolid tumoursMelanomaLymphoma +[4]

Other Information

ATC CodeN/A